DE69631842D1 - Verfahren zum Entwerfen und Herstellung von zielmolekulbindenden Liganden - Google Patents

Verfahren zum Entwerfen und Herstellung von zielmolekulbindenden Liganden

Info

Publication number
DE69631842D1
DE69631842D1 DE69631842T DE69631842T DE69631842D1 DE 69631842 D1 DE69631842 D1 DE 69631842D1 DE 69631842 T DE69631842 T DE 69631842T DE 69631842 T DE69631842 T DE 69631842T DE 69631842 D1 DE69631842 D1 DE 69631842D1
Authority
DE
Germany
Prior art keywords
ligand
target molecule
subsequent
moieties
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631842T
Other languages
English (en)
Inventor
Stephen W Fesik
Philip J Hajduk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24218250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69631842(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of DE69631842D1 publication Critical patent/DE69631842D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compounds Of Iron (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69631842T 1995-11-14 1996-11-13 Verfahren zum Entwerfen und Herstellung von zielmolekulbindenden Liganden Expired - Lifetime DE69631842D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/555,691 US5698401A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to identify ligands to target biomolecules

Publications (1)

Publication Number Publication Date
DE69631842D1 true DE69631842D1 (de) 2004-04-15

Family

ID=24218250

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69631842T Expired - Lifetime DE69631842D1 (de) 1995-11-14 1996-11-13 Verfahren zum Entwerfen und Herstellung von zielmolekulbindenden Liganden
DE69606324T Expired - Lifetime DE69606324T3 (de) 1995-11-14 1996-11-13 Verwendung von magnetischer kernresonanz zur identifizierung von liganden für zielbiomoleküle

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69606324T Expired - Lifetime DE69606324T3 (de) 1995-11-14 1996-11-13 Verwendung von magnetischer kernresonanz zur identifizierung von liganden für zielbiomoleküle

Country Status (13)

Country Link
US (2) US5698401A (de)
EP (2) EP0981049B1 (de)
JP (1) JP3032301B2 (de)
AT (2) ATE261581T1 (de)
AU (1) AU701810B2 (de)
CA (1) CA2237343C (de)
DE (2) DE69631842D1 (de)
DK (1) DK0866967T4 (de)
ES (1) ES2143793T5 (de)
GR (1) GR3032361T3 (de)
IL (2) IL123923A (de)
PT (1) PT866967E (de)
WO (1) WO1997018471A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
US5989827A (en) * 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
AU2426697A (en) 1996-03-29 1997-10-22 Lawrence Berkeley National Laboratory Enhancement of nmr and mri in the presence of hyperpolarized noble gases
DE19649359C1 (de) * 1996-11-28 1998-02-12 Thomas Prof Dr Peters Verfahren zum Nachweis biologisch aktiver Substanzen in Substanzbibliotheken
AU772620B2 (en) * 1997-04-18 2004-05-06 Abbvie Inc. Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
US6043024A (en) * 1997-04-18 2000-03-28 Abbott Laboratories Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
EP0988528A1 (de) * 1997-06-13 2000-03-29 Vertex Pharmaceuticals Incorporated Methoden zur identifikation von medikamentenkernen
US20030143757A1 (en) * 1997-06-13 2003-07-31 Jonathan Moore Methods for identifying drug cores
US6111066A (en) * 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
US6288234B1 (en) * 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US7501236B1 (en) * 1998-12-30 2009-03-10 Ge Healthcare Limited NMR spectroscopic in vitro assay using hyperpolarization
US6897337B2 (en) * 1999-04-09 2005-05-24 Abbott Laboratories Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
TWI283659B (en) * 1999-04-09 2007-07-11 Abbott Lab Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6333149B1 (en) 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6171804B1 (en) 1999-07-12 2001-01-09 The Rockefeller University Method of determining interdomain orientation and changes of interdomain orientation on ligation
AU6115300A (en) * 1999-07-19 2001-02-05 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
US7105310B1 (en) * 2000-07-19 2006-09-12 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
JP2003522325A (ja) * 1999-08-23 2003-07-22 ポラリス ファーマシューティカルズ，インコーポレイテッド タンパク質と巨大分子リガンドとの結合阻害剤
US6677160B1 (en) * 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
ES2331050T3 (es) * 1999-09-29 2009-12-21 Nerviano Medical Sciences S.R.L. Metodos para creacion de una biblioteca de compuestos e identificacion de modelos y ligandos quimicos lideres para moleculas diana.
JP2003510608A (ja) * 1999-09-29 2003-03-18 スミスクライン・ビーチャム・コーポレイション 標的生体分子と相互作用する化合物を同定するための一次元および多次元核磁気共鳴の使用法
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
BR0108606A (pt) * 2000-02-25 2003-01-07 Wyeth Corp Métodos de planejamento de droga com base na estrutura empregando-se em/rmn
WO2001079852A2 (en) * 2000-04-17 2001-10-25 Pharmacia & Upjohn Company Nmr-methods for indentifying sites in papillomavirus e2 protein
GB0013115D0 (en) * 2000-05-31 2000-07-19 Imp College Innovations Ltd Biological materials and methods for use in the prevention or treatment of infections
US7146277B2 (en) * 2000-06-13 2006-12-05 James H. Prestegard NMR assisted design of high affinity ligands for structurally uncharacterized proteins
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
EP2280272A1 (de) 2000-09-27 2011-02-02 Universiteit Leiden Verfahren zur Anwendung der Kernspinresonanz zur Entdeckung von Liganden oder als ein Werkzeug zum Aussieben von medizinisch wirksamen Substanzen
SE0003811D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Screening methods
AU2002256556A1 (en) * 2000-12-21 2002-07-01 Triad Therapeutics, Inc Sea-trosy and related methods
US6924302B2 (en) * 2000-12-22 2005-08-02 Ortho Mcneil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
US7645569B2 (en) * 2001-01-26 2010-01-12 Board Of Regents, The University Of Texas System NMR detection of foreign PAS domain ligands
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
DE10119455B4 (de) * 2001-04-20 2010-12-16 Siemens Ag Verfahren zum Auswerten von Daten, die mittels der Magnetresonanztechnik erzeugt werden und spektroskopische Information beinhalten
US7300922B2 (en) 2001-05-25 2007-11-27 Duke University Modulators of pharmacological agents
US20030008326A1 (en) * 2001-05-30 2003-01-09 Sem Daniel S Nuclear magnetic resonance-docking of compounds
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
US7653490B2 (en) * 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
DE10144661C2 (de) * 2001-09-11 2003-08-14 Forschungsverbund Berlin Ev Vorrichtung und Verfahren zur Zuordnung der NMR-Signale von Polypeptiden
US7179450B2 (en) * 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
WO2003040400A2 (en) * 2001-11-06 2003-05-15 Message Pharmaceuticals, Inc. Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
DE10160177A1 (de) * 2001-12-07 2003-06-26 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden die an ein drug target binden mittels 1H,1H-Kernresonanzspektroskopie
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20030180797A1 (en) * 2002-03-20 2003-09-25 Lin Yu Identification of ligands for a receptor family and related methods
AU2003253589A1 (en) * 2002-03-26 2003-11-10 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
DE10221158A1 (de) * 2002-05-13 2004-02-19 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden, die an ein drug target binden, mittels heteronuklearer Kernresonanzspektroskopie
US20060154323A1 (en) * 2002-06-10 2006-07-13 Prospect Pharma Method for obtaining dynamic and structural data pertaining to proteins and protein/ligand complexes
US20040142864A1 (en) * 2002-09-16 2004-07-22 Plexxikon, Inc. Crystal structure of PIM-1 kinase
WO2006078228A1 (en) * 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20040132102A1 (en) * 2002-10-29 2004-07-08 Maurizio Pellecchia Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy
NO20025738D0 (no) * 2002-11-29 2002-11-29 Amersham Health As Metode
US20050170431A1 (en) * 2003-02-28 2005-08-04 Plexxikon, Inc. PYK2 crystal structure and uses
WO2004083814A2 (en) * 2003-03-13 2004-09-30 Triad Therapeutics, Inc. Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes
US20040265909A1 (en) * 2003-04-11 2004-12-30 Jeff Blaney Compound libraries and methods for drug discovery
WO2004095028A1 (ja) * 2003-04-23 2004-11-04 Olympus Corporation 受容体に結合可能な物質をスクリーニングする方法
JP2004331832A (ja) * 2003-05-08 2004-11-25 Ricoh Co Ltd Ｄｎａインク組成物とそれを用いた識別画像印刷体、及びインクジェット記録装置
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7255985B2 (en) * 2003-07-10 2007-08-14 Pfizer Italia S.R.L. Fluorine NMR spectroscopy for biochemical screening
US20050164300A1 (en) * 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
EP1678198A4 (de) * 2003-10-07 2007-12-05 Prospect Pharma Seitenkettendeuterierte aminosäuren und anwendungsverfahren
JP4192078B2 (ja) * 2003-11-26 2008-12-03 株式会社日立製作所 核磁気共鳴方法
JP4546400B2 (ja) * 2003-11-28 2010-09-15 株式会社日立製作所 核磁気共鳴法を用いた、標的タンパク質のアゴニストおよびアンタゴニストの同定方法、およびこの方法に用いるプログラム
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
US7771938B2 (en) 2004-09-20 2010-08-10 Wisconsin Alumni Research Foundation Nonlinear spectroscopic methods for identifying and characterizing molecular interactions
WO2006082963A1 (ja) * 2005-02-07 2006-08-10 Mitsubishi Chemical Corporation 標的分子とリガンドあるいはリガンド候補化合物との結合検出方法
US20090239760A1 (en) 2006-03-14 2009-09-24 University Of Basel Method for the Identification of New Leads for Drug Candidates
US8933209B2 (en) 2006-04-26 2015-01-13 Abbvie Inc. Dep2 and its uses in major depressive disorder and other related disorders
US7760342B2 (en) 2007-12-21 2010-07-20 Wisconsin Alumni Research Foundation Multidimensional spectrometer
JPWO2012108297A1 (ja) * 2011-02-07 2014-07-03 国立大学法人神戸大学 Ｒａｓ部分ポリペプチド含有水溶液及びＲａｓ機能阻害剤のスクリーニング方法
CA2861392C (en) 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
IL257458B2 (en) 2015-08-11 2024-01-01 Arch Biopartners Inc DPEP-1 binding compositions and methods of use
JP7123932B2 (ja) 2016-09-02 2022-08-23 クリストファー ジェイ． ソアレス 神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE904705A1 (en) * 1989-12-29 1991-07-17 Univ Technologies Int Methods for modelling tertiary structures of biologically¹active ligands including agonists and antagonists thereto¹and novel synthetic antagonists based on angiotensin
US5164297A (en) * 1990-05-03 1992-11-17 Advanced Magnetics Inc. Solvent mediated relaxation assay system
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
EP0593618B1 (de) * 1991-06-27 1998-04-22 Genelabs Technologies, Inc. Screeningtest für den nachweis von dna-bindenden molekülen

Also Published As

Publication number Publication date
EP0866967B2 (de) 2007-08-08
IL155988A0 (en) 2003-12-23
MX9803810A (es) 1998-09-30
WO1997018471A1 (en) 1997-05-22
DE69606324D1 (de) 2000-02-24
US5698401A (en) 1997-12-16
IL123923A (en) 2005-07-25
EP0866967B1 (de) 2000-01-19
AU7732896A (en) 1997-06-05
AU701810B2 (en) 1999-02-04
DK0866967T3 (da) 2000-06-26
US5804390A (en) 1998-09-08
ATE261581T1 (de) 2004-03-15
EP0866967A1 (de) 1998-09-30
DK0866967T4 (da) 2007-12-10
JP3032301B2 (ja) 2000-04-17
IL155988A (en) 2005-07-25
DE69606324T3 (de) 2008-02-07
GR3032361T3 (en) 2000-04-27
CA2237343A1 (en) 1997-05-22
PT866967E (pt) 2000-04-28
ATE189063T1 (de) 2000-02-15
ES2143793T3 (es) 2000-05-16
CA2237343C (en) 2009-01-20
EP0981049A1 (de) 2000-02-23
JPH11513498A (ja) 1999-11-16
DE69606324T2 (de) 2000-07-06
ES2143793T5 (es) 2008-03-01
EP0981049B1 (de) 2004-03-10

Similar Documents

Publication Publication Date Title
DE69631842D1 (de) Verfahren zum Entwerfen und Herstellung von zielmolekulbindenden Liganden
CA2653517A1 (en) Process of designing a drug
DE69619825D1 (de) Kombinatorische bibliotheken aus markierten biochemischen verbindungen und verfahren zu ihrer herstellung
ATE197156T1 (de) Verfahren zum nachweis von verbindungen einer konbinatorischen bibliothek.
DE59004417D1 (de) Verfahren zum Färben von Leder.
GR3036454T3 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
FR2714746B1 (fr) Procédé de simulation d'une architecture "serveur" à partir d'une architecture "client".
DE59007200D1 (de) Verfahren zur Bestimmung eines Analyten.
DE69628194D1 (de) Verfahren zum nachweis von verbindungen die bestimmte zielmoleküle binden
DE69001623D1 (de) Verfahren zur herstellung von fluor-oxy-fluorsulfonylverbindungen durch direkte fluorierung von fluor-beta-sultonen.
DE58909090D1 (de) Verfahren zum Farben von Leder.
DE69638114D1 (de) Verfahren zum entwurf einer physiologisch aktiven verbindung
DE3869244D1 (de) Verfahren zum wiederaufbau von durch dreidimensionales experimentieren erworbenen bildern, insbesondere in nmr.
DE69610974D1 (de) Verfahren zum Beschichten von Leder
FR2693813B1 (fr) Procédé de réalisation d'une image de référence synthétisée à partir de données contenues dans une base de données CAO.
DE59203324D1 (de) Verfahren zum Färben von Leder.
FR2709851B1 (fr) Procédé de reconstruction d'une image tridimensionnelle par histoprojections.
IT8902504A0 (it) Metodo di eliminazione dell'abbigliamento automobilistico, per mezzo di coppia di filtri polarizzatori.
DE69013543D1 (de) Verfahren zur Modifikation eines Metallkomplexes.

Legal Events

Date Code Title Description
8332 No legal effect for de